Publications

M. Kufa, V. Finger, O. Kovar, O. Soukup, C. Torruellas, J. Roh, J. Korabecny. Revolutionizing tuberculosis treatment: breakthroughs, challenges, and hope on the horizon. Acta Pharm Sinica B, 2025, accepted  (IF₂₀₂₃ = 14.8) (D_AIS1)

L. Konečný, Z. Lomozová, G. Karabanovich, J. Roh, K. Vávrová, P. Mladěnka. Rapid method for screening of both calcium and magnesium chelation with comparison of 21 known metal chelators. J. Biol. Inorg. Chem., 2024, 29, 785–800

V. Kerestes, J. Kubes, L. Applova, P. Kollarova, O. Lencova-Popelova, I. Melnikova, G. Karabanovich, M. M. Khazeem, H. Bavlovic-Piskackova, P. Sterbova-Kovarikova, C. A. Austin,  J. Roh, M. Sterba, T. Simunek, A. Jirkovska. Exploring the effects of topoisomerase II inhibitor XK469 on anthracycline cardiotoxicity and DNA damage. Tox. Sci. 2024. 198 (2), 288–302. (IF₂₀₂₂ = 3.8) (Q_AIS1)

G. Karabanovich, V. Fabiánová, A. Vocat, J. Dušek, L. Valášková, J. Stolaříková, R. R. A. Kitson, P. Pávek, K. Vávrová, K. Djaout, K. Mikušová, A. R. Baulard, S. T. Cole, J. Korduláková, J. Roh*. Both nitro groups are essential for high antitubercular activity of 3,5-dinitrobenzylsulfanyl tetrazoles and 1,3,4-oxadiazoles through the deazaflavin-dependent nitroreductase activation pathway. J. Med. Chem. 2024, 67, 81-109. (IF₂₀₂₂ = 7.3) (D_AIS1)

V. Finger, T. Kucera, R. Kafkova, L. Muckova, R. Dolezal, J. Kubes, M. Novak, L. Prchal, L. Lakatos, M. Andrs, M. Hympanova, J. Marek, M. Kufa, V. Spiwok, O. Soukup, E. Mezeiova, J. Janousek, L. Nevosadova, M. Benkova, R.R.A. Kitson, M. Kratky, S. Bősze, K. Mikusova, R. Hartkoorn, J. Roh*, J. Korabecny*, 2,6-Disubstituted 7-(naphthalen-2-ylmethyl)-7H-purines as a new class of potent antitubercular agents inhibiting DprE1, Eur. J. Med. Chem. 2023, 258, 115611. (IF₂₀₂₂ = 6.7) (Q_AIS1)

P. Hatokova, V. Sestak, H. Bavlovic Piskackova, I. Melnikova, J. Roh, P. Sterbova-Kovarikova. The UHPLC-UV method applied for the forced degradation study of ixazomib and HRMS identification of its degradation products. J. Pharm. Biomed. Anal. 2023, 225, 115220. (IF₂₀₂₁ = 3.571) (Q_AIS2, 3)

V. Finger, M. Kufa, O. Soukup, D. Castagnolo, J. Roh*, J. Korabecny.* Pyrimidine derivatives with antitubercular activity. Eur. J. Med. Chem. 2023, 15(246), 114946. (IF₂₀₂₂ = 6.7) (Q_AIS1)

M. Kopecna, M. Machacek, J. Roh, K. Vavrova. Proline, hydroxyproline, and pyrrolidone carboxylic acid derivatives as highly efficient but reversible transdermal permeation enhancers. Sci. Rep. 2022, 12(1), 19495. (IF₂₀₂₁ = 4.997) (Q_AIS2)

L. Gorecki, D. Muthna, S. Merdita, M. Andrs, T. Kucera, R. Havelek, L. Muckova, T. Kobrlova, J. Soukup, P. Krupa, L. Prchal, O. Soukup, J. Roh, M. Rezacova, J. Korabecny. 7-Azaindole, 2,7-diazaindole, and 1H-pyrazole as core structures for novel anticancer agents with potential chemosensitizing properties. Eur. J. Med. Chem. 2022, 240, 114580. (IF₂₀₂₁ = 7.088) (Q_AIS1)

P. Haskova, L. Applova, H. Jansova, P. Homola, K. J. Franz, K. Vavrova, J. Roh, T. Simunek. Examination of diverse iron-chelating agents for the protection of differentiated PC12 cells against oxidative injury induced by 6-hydroxydopamine and dopamine. Sci. Rep. 2022, 12, 9765. (IF₂₀₂₁ = 4.997) (Q_AIS2)

E. Jirkovský, A. Jirkovská, H. Bavlovič-Piskáčková, V. Skalická, Z. Pokorná, G. Karabanovich, P. Kollárová-Brázdová, J. Kubeš, O. Lenčová-Popelová, Y. Mazurová, M. Adamcová, A. R. Lyon, J. Roh, T. Šimůnek, P. Štěrbová-Kovaříková, M. Štěrba. Clinically Translatable Prevention of Anthracycline Cardiotoxicity by Dexrazoxane Is Mediated by Topoisomerase II Beta and Not Metal Chelation. Circ Heart Fail. 2021;14: e008209. (IF₂₀₂₁ = 10.447) (D_AIS1)

P. Kollárová-Brázdová, O. Lencova-Popelova, G. Karabanovich; J. Kocúrová-Lengvarská, J. Kubes, N. Váňová, Y. Mazurova, M. Adamcova, A. Jirkovska, M. Holečková, T. Šimůnek, P. Štěrbová-Kovaříková, J. Roh, M. Štěrba. Prodrug of ICRF-193 provides promising protective effects against chronic anthracycline cardiotoxicity on a rabbit model in vivo. Clin. Sci. 2021. 135, 1897–1914. (IF₂₀₂₁ = 6.876) (Q_AIS1)

A. Jirkovská, G. Karabanovich, J. Kubeš, V. Skalická, I. Melnikova, J. Korábečný, T. Kučera, E. Jirkovský, L. Nováková, H. Bavlovič Piskáčková, J. Škoda, M. Štěrba, C. A. Austin, T. Šimůnek, J. Roh*. Structure−Activity Relationship Study of Dexrazoxane Analogues Reveals ICRF-193 as the Most Potent Bisdioxopiperazine against Anthracycline Toxicity to Cardiomyocytes Due to Its Strong Topoisomerase IIβ Interactions. J. Med. Chem. 2021, 64, 3997-4019. (IF₂₀₂₁ = 8.039) (D_AIS1)

H. Bavlovič Piskáčková, H. Jansová, J. Kubeš, G. Karabanovich, N. Váňová, P. Kollárová-Brázdová, I. Melnikova, A. Jirkovská, O. Lenčová-Popelová, J. Chládek, J. Roh, T. Šimůnek, M. Štěrba, P. Štěrbová-Kovaříková. Development of water-soluble prodrugs of the bisdioxopiperazine topoisomerase IIβ inhibitor ICRF 193 as potential cardioprotective agents against anthracycline cardiotoxicity. Scientific Reports. 2021, 11, 4456. (IF₂₀₂₁ = 4.996) (Q_AIS2)

N. Monakhova, J. Kordulakova, A. Vocat, A. Egorova, A. Lepioshkin, E. G. Salina, J. Nosek, E. Repkova, J. Zemanova, H. Jurdakova, R. Gorova, J. Roh, G. Degiacomi, J. C. Sammartino, M. R. Pasca, S. T. Cole, K. Mikusova, V. Makarov. Design and Synthesis of Pyrano[3,2-b]indolones Showing Antimycobacterial Activity. ACS Infect. Dis. 2021, 7(1), 88-100. (IF₂₀₂₁ = 5.578) (D_AIS1)

P. Kollárová-Brázdová, A. Jirkovská, G. Karabanovich, Z. Pokorná, H. Bavlovič Piskáčková, E. Jirkovský, J. Kubeš, O. Lenčová-Popelová, Y. Mazurová, M. Adamcová, V. Skalická, P. Štěrbová-Kovaříková, J. Roh, T. Šimůnek and M. Štěrba. Investigation of Structure-Activity Relationships of Dexrazoxane Analogs Reveals Topoisomerase IIβ Interaction as a Prerequisite for Effective Protection against Anthracycline Cardiotoxicity. Journal of Pharmacology and Experimental Therapeutics 2020, 373(3), 402-415. (IF₂₀₂₀ = 4.030)  (Q_AIS1)

M. Kopecna, M. Machacek, A. Novackova, G. Paraskevopoulos, J. Roh, K. Vavrova. Esters of terpene alcohols as highly potent, reversible, and low toxic skin penetration enhancers. Sci. Rep. 2019, 9, 14617. (IF₂₀₁₉ = 3.998) (Q1)

G. Karabanovich, J. Dušek, K. Savková, O. Pavliš, I. Pávková, J. Korabecny, T. Kučera, H. Kočová Vlčková, S. Huszár, Z. Konyariková, K. Konečná, O. Jandourek, J. Stolaříková, J. Korduláková, K. Vávrová, P. Pavek, V. Klimešová, A. Hrabalek, K. Mikušová, J. Roh*. Development of 3,5-Dinitrophenyl-Containing 1,2,4-Triazoles and their Trifluoromethyl Analogues as Highly Efficient Antitubercular Agents Inhibiting Decaprenylphosphoryl-β-D-ribofuranose 2′-Oxidase. J. Med. Chem. 2019,62, 8115-8139. (IF₂₀₁₉ = 6.205) (Q1)

P. Reimerova; J. Stariat, H. Piskackova, H. Jansova, J. Roh, D.S. Kalinowski, M. Machacek, T. Simunek, D. R. Richardson, P. Sterbova-Kovarikova. Novel SPME fibers based on a plastic support for determination of plasma protein binding of thiosemicarbazone metal chelators: a case example of DpC, an anti-cancer drug that entered clinical trials. Anal. Bioanal. Chem. 2019, 411(11), 2383-2394. (IF₂₀₁₉ = 3.637) (Q1)

P. Reimerova, A. Jirkovska, H. Piskackova, G. Karabanovich, J. Roh, T. Simunek, P. Sterbova-Kovarikova. UHPLC-MS/MS method for analysis of sobuzoxane, its active form ICRF-154 and metabolite EDTA-diamide and its application to bioactivation study.  Sci. Rep. 2019, 9, Art. No. 4524. (IF₂₀₁₉ = 3.998) (Q1)

H. Jansová, J. Kubeš, P. Reimerová, P. Štěrbová-Kovaříková, J. Roh*, and T. Šimůnek.* 2,6-Dihydroxybenzaldehyde Analogues of the Iron Chelator Salicylaldehyde Isonicotinoyl Hydrazone: Increased Hydrolytic Stability and Cytoprotective Activity against Oxidative Stress. Chem. Res. Toxicol., 2018, 31 (11), 1151–1163. (IF₂₀₁₈ = 3.274)

E. Jirkovský, A. Jirkovská, J. Bureš, J. Chládek, O. Lenčová, J. Stariat, Z. Pokorná, G. Karabanovich, J. Roh, P. Brázdová, T. Šimůnek, P. Kovaříková, M. Štěrba. Pharmacokinetics of the cardioprotective drug dexrazoxane and its active metabolite ADR-925 with focus on cardiomyocytes and the heart. Journal of Pharmacology and Experimental Therapeutics. 2018, 364 (3), 433-446. (IF₂₀₁₈ = 3.615) (Q1)

J. Bureš, A. Jirkovská, V. Šesták, H. Jansová, G. Karabanovich, J. Roh, M. Štěrba, T. Šimůnek, P. Kovaříková. Investigation of novel dexrazoxane analogue JR-311 shows significant cardioprotective effects through topoisomerase IIbeta but not its iron chelating metabolite. Toxicology 2017, 392, 1-10. (IF₂₀₁₇ = 3.265)

I. Melnikova, J. Roh, J. Kuneš, T. Artamonova, Y. Zevatskii, L. Myznikov. Non-catalyzed addition of heterocyclic thiols and 5-substituted-1H-tetrazoles to vinyl ethers. Tetrahedron Lett. 2017, 58, 3842–3845. (IF₂₀₁₇ = 2.125)

J. Roh *, G. Karabanovich, H. Vlčková, A. Carazo, J. Němeček, P. Sychra, L. Valášková, O. Pavliš, J. Stolaříková, V. Klimešová, K. Vávrová, P. Pávek, A. Hrabálek. Development of Water-Soluble 3,5-Dinitrophenyl Tetrazole and Oxadiazole Antitubercular Agents. Bioorg. Med. Chem. 2017, 25, 5468–5476. (IF₂₀₁₇ = 2.881)

E. Mezeiova, J. Korabecny, V. Sepsova, M. Hrabinova, P. Jost, L. Muckova, T. Kucera, R. Dolezal, J. Misik, K. Spilovska, N. L. Pham, L. Pokrievkova, J. Roh, D. Jun, O. Soukup, D. Kaping, K. Kuca. Development of 2-Methoxyhuprine as Novel Lead for Alzheimer’s Disease Therapy. Molecules 2017, 22, 1265. (IF₂₀₁₇ = 3.098)

J. Němeček, P. Sychra, M. Macháček, M. Benková, G. Karabanovich, K. Konečná, V. Kavková, J. Stolaříková, A. Hrabálek, K. Vávrová, O. Soukup, J. Roh,* V. Klimešová. Structure-activity relationship studies on 3,5-dinitrophenyl tetrazoles as antitubercular agents. Eur. J. Med. Chem. 2017, 130, 419–432. (IF₂₀₁₇ = 4.816) (Q1)

G. Karabanovich, J. Němeček, L. Valášková, A. Carazo, K. Konečná, J. Stolaříková, A. Hrabálek, O. Pavliš, P. Pávek, K. Vávrová, J. Roh,* V. Klimešová. S-Substituted 3,5-Dinitrophenyl 1,3,4-Oxadiazole-2-thiols and Tetrazole-5-thiols as Highly Efficient Antitubercular Agents. Eur. J. Med. Chem. 2017, 126, 369-383. (IF₂₀₁₇ = 4.816) (Q1)

J. Roh,* G. Karabanovich, V. Novakova, T. Šimůnek, K. Vávrová. Large-scale synthesis of piperazine-2,6-dione and its use in the synthesis of dexrazoxane analogues. Synthesis. 2016, 48, 4580-4588. (IF₂₀₁₆ = 2.650)

A. Kováčik, L. Opálka, M. Šilarová, J. Roh, K. Vávrová. Synthesis of 6-hydroxyceramide using rutheniumcatalyzed hydrosilylation–protodesilylation. Unexpected formation of a long periodicity lamellar phase in skin lipid membranes. RSC Advances, 2016, 6, 73343–73350. (IF₂₀₁₆ = 3.108)

H. Jansová, J. Bureš, M. Macháček, P. Hašková, A. Jirkovská, J. Roh, Q. Wang, K. J. Franz, P. Kovaříková, T. Šimůnek. Characterization of cytoprotective and toxic properties of iron chelator SIH, prochelator BSIH and their degradation products. Toxicology, 2016, 350, 15–24. (IF₂₀₁₆ = 3.582) (Q1)

V. Sestak , J. Roh, L. Klepalova, P. Kovarikova. A UHPLC-UV-QTOF Study on the Stability of Carfilzomib, A Novel Proteasome Inhibitor. Journal of Pharmaceutical and Biomedical Analysis, 2016, 124, 365–373. (IF₂₀₁₆ = 3.255) (Q1)

G. Karabanovich, J. Zemanová, T. Smutný, R. Székely, M. Šarkan, I. Centárová, A. Vocat, I. Pávková, P. Čonka, J. Němeček, J. Stolaříková, M. Vejsová, K. Vávrová, V. Klimešová, A. Hrabálek, P. Pávek, S. T. Cole, K. Mikušová, J. Roh.* Development of 3,5-Dinitrobenzylsulfanyl-1,3,4-Oxadiazoles and Thiadiazoles as Selective Antitubercular Agents Active Against Replicating and Nonreplicating Mycobacterium tuberculosis. J. Med. Chem. 2016, 59, 2362−2380. (IF₂₀₁₆ = 6.259) (Q1)

L. Lochman, J. Svec, J. Roh, K. Kirakci, K. Lang, P. Zimcik, V. Novakova. Metal-Cation Recognition in Water by a Tetrapyrazinoporphyrazine-Based Tweezer Receptor. Chem. Eur. J., 2016, 22(7), 2417-2426. (IF₂₀₁₆ = 5.317) (Q1)

V. Sestak, J. Stariat, J. Cermanova, E. Potuckova, J. Chladek, J. Roh, J. Bures, H. Jansova, P. Prusa, M. Sterba, S. Micuda, T. Simunek, D. S. Kalinowski, D. R. Richardson, P. Kovarikova. Novel and potent anti-tumor and anti-metastatic di-2-pyridylketone thiosemicarbazones demonstrate marked differences in pharmacology between the first and second generation lead agents. Oncotarget, 2016, 6 (40), 42411-42428. (IF₂₀₁₆ = 5.168) (Q1)

L. Opálka, A. Kováčik, M. Sochorová, J. Roh, J. Kuneš, J. Lenčo, K. Vávrová. Scalable Synthesis of Human Ultralong Chain Ceramides. Org. Lett., 2015, 17 (21), 5456–5459. (IF₂₀₁₅ = 6.732) (Q1)

E. Potůčková, J. Roh, M. Macháček, S. Sahni, J. Stariat, V. Šesták, H. Jansová, P. Hašková, A. Jirkovská, K. Vávrová, P. Kovaříková, D. S. Kalinowski, D. R. Richardson, T. Šimůnek. In Vitro Characterization of the Pharmacological Properties of the Anti-Cancer Chelator, Bp4eT, and Its Phase I Metabolites. PLoS ONE 2015, 10 (10). e0139929. (IF₂₀₁₅ = 3.057) (Q1)

A. Jirkovska, J. Roh, O. Lenčová-Popelová, E. Jirkovsky, K. Hruskova, E. Potuckova, H. Jansova, P. Haskova, P. Martinkova, T. Eisner, M. Kratochvil, J. Sus, M. Machacek, L. Tichotova, V. Gersl, D. S. Kalinowski, M. Muller, D. Richardson, K. Vavrova, M. Sterba, T. Simunek. Synthesis and analysis of novel analogues of dexrazoxane and its open-ring hydrolysis product for protection against anthracycline cardiotoxicity in vitro and in vivo. Toxicol. Res. 2015, 4, 1098–1114. (IF₂₀₁₅ = 2.161)

L. Lochman, J. Svec, J. Roh, V. Novakova. The role of the size of aza-crown recognition moiety in azaphthalocyanine fluorescence sensors for alkali and alkaline earth metal cations. Dyes Pigment. 2015, 121, 178-187. (IF₂₀₁₅ = 4.055) (Q1)

G. Karabanovich, J. Roh,* O. Soukup, I. Pávková, M. Pasdiorová, V. Tambor, J. Stolaříková, M. Vejsová, K. Vávrová, V. Klimešová, A. Hrabálek. Tetrazole Regioisomers in the Development of Nitro Group-Containing Antitubercular Agents. Med. Chem. Commun. 2015, 6, 174-181. (IF₂₀₁₅ = 2.319)

B. Skolova, K. Hudska, P. Pullmannova, A. Kovacik, K. Palat, J. Roh, J. Fleddermann, I. Estrela-Lopis, K. Vavrova. Different Phase Behavior and Packing of Ceramides with Long (C16) and Very Long (C24) Acyls in Model Membranes: Infrared Spectroscopy Using Deuterated Lipids. J. Phys. Chem. B 2014, 118 (35), 10460-10470. (IF₂₀₁₄ = 3.302)

G. Karabanovich, J. Roh,* T. Smutný, J. Něměcek, P. Vicherek, J. Stolaříková, M. Vejsová, I. Dufková, K. Vávrová, P. Pávek, V. Klimešová, A. Hrabálek. 1-Substituted-5-[(3,5-dinitrobenzyl)sulfanyl]-1H-tetrazoles and their isosteric analogs: A new class of selective antitubercular agents active against drug-susceptible and multidrug-resistant mycobacteria. Eur. J. Med. Chem. 2014, 82, 324-340. (IF₂₀₁₄ = 3.447) (Q1)

A. Kovacik, J. Roh, K. Vavrova. The Chemistry and Biology of 6-Hydroxyceramide, the Youngest Member of the Human Sphingolipid Family. ChemBioChem 2014, 15 (11), 1555-1562. (IF₂₀₁₄ = 3.088)

B. Skolova, K. Jandovska, P. Pullmannova, O. Tesar, J. Roh, A. Hrabalek, K. Vavrova. The Role of the Trans Double Bond in Skin Barrier Sphingolipids: Permeability and Infrared Spectroscopic Study of Model Ceramide and Dihydroceramide Membranes. Langmuir 2014, 30 (19), 5527-5535. (IF₂₀₁₄ = 4.457) (Q1)

J. Stariat, V. Suprunova, J. Roh, V. Sestak, T. Eisner, T. Filipsky, P. Mladenka, M. Nobilis, T. Simunek, J. Klimes, D. S. Kalinowski, D. R. Richardson, P. Kovarikova. Simultaneous determination of the novel thiosemicarbazone anti-cancer agent, Bp4eT, and its main phase I metabolites in plasma: Application to a pilot pharmacokinetic study in rats. Biomed. Chromatogr. 2014, 28 (5), 621-629. (IF₂₀₁₄ = 1.723)

D. Diblikova, M. Kopecna, B. Skolova, M. Krecmerova, J. Roh, A. Hrabalek, K. Vavrova. Transdermal Delivery and Cutaneous Targeting of Antivirals using a Penetration Enhancer and Lysolipid Prodrugs. Pharm. Res. 2014, 31 (4), 1071-1081. (IF₂₀₁₄ = 3.420) (Q1)

B. Školová, B. Janůšová, J. Zbytovská, G. Gooris, J. A. Bouwstra, P. Slepička, P. Berka, J. Roh, K. Palát, A. Hrabálek, K. Vávrová. Ceramides in the Skin Lipid Membranes: Length Matters. Langmuir 2013, 29, 15624-15633. (IF₂₀₁₃ = 4.384) (Q1)

G. Karabanovich, J. Roh,* Z. Padělková, Z. Novák, K. Vávrová, A. Hrabálek, One-pot synthesis of 1-substituted-5-alkylselanyl-1H-tetrazoles from isoselenocyanates: Unexpected formation of N-alkyl-N-arylcyanamides and (Z)-Se-alkyl-N-cyano-N,N’-diarylisoselenoureas. Tetrahedron 2013, 69, 8798-8808. (IF₂₀₁₃ = 2.817)

L. Myznikov, U. Dmitrieva, T. Artamonova, J. Roh, A. Hrabálek, Y. Zevatskii, An Efficient Synthesis of 1-Substituted 5-Bromo-1H-tetrazoles. Synthesis 2013, 45, 2029-2033. (IF₂₀₁₃ =2.443)

B. Janůšová, B. Školová, K. Tükörová, L. Wojnarová, T. Šimůnek, P. Mladěnka, T. Filipský, M. Říha, J. Roh, K. Palát, A. Hrabálek, K. Vávrová, Amino acid derivatives as transdermal permeation enhancers. J. Control. Release 2013, 165 (2), 91-100. (IF₂₀₁₃ = 7.261) (Q1)

J. Roh,* K. Vavrova, A. Hrabalek, Synthesis and Functionalization of 5-Substituted Tetrazoles, Eur. J. Org. Chem., 2012, 6101–6118. (IF₂₀₁₂ = 3.344) (Q1)

V. Novakova, J. Roh, P. Gela, J. Kuneš, P. Zimcik, Azaphthalocyanines with fused triazolo rings: formation of sterically stressed constitutional isomers. Chem. Commun. 2012, 48, 4326-4328. (IF₂₀₁₂ = 6.378) (Q1)

K. Vávrová, P. Kovaříková, B. Školová, M. Líbalová, J. Roh, R. Čáp, A. Holý, A. Hrabálek, Enhanced topical and transdermal delivery of antineoplastic and antiviral acyclic nucleoside phosphonate cPr‑PMEDAP. Pharm. Res. 2011; 28 (12), 3105-3115. (IF₂₀₁₁ = 4.093) (Q1)

J. Roh,* K. Vávrová, A. Hrabálek. One-pot regioselective vinylation of tetrazoles: preparation of 5-substituted 2-vinyl-2H-tetrazoles. Tetrahedron Lett. 2010, 51 (10), 1411–1414. (IF₂₀₁₀ = 2.618)

J. Roh,* T. V. Artamonova, K. Vávrová, G. I. Koldobskii, A. Hrabálek, Practical Synthesis of 5-Substituted Tetrazoles under Microwave Irradiation. Synthesis 2009, (13), 2175-2178. (IF₂₀₀₉ = 2.572)